Astrazeneca

FASENRA

Manufacturer:

Astrazeneca

Fasenra HCPCS:

J0517

HCPCS Code Descriptor:

Injection, benralizumab, 1 mg

Category:

J Code

Fasenra NDCs:

00310-1830-30, 00310-1730-30

Primary Type:

Anti-Eosinophil Asthma

Generic/Specialty Status:

Single-Source

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Fasenra:

FASENRA is an Anti-Eosinophil Asthma drug manufactured by Astrazeneca and administered via the Subcutaneous route of administration. The J Code: J0517 is aligned to the drug FASENRA.

ACCESS PRICING AND MORE BY REGISTERING

J0517 Added Date:

January 1, 2019

J0517 Effective Date:

January 1, 2019

J0517 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Fasenra billing and coding information.
Fasenra patient assistance information can be found through The AZ&Me Prescription Savings Program at the URL: https://www.azandmeapp.com/prescriptionsavings/
FASENRA prescribing information can be found at the link below:
Information regarding FASENRA’s side effects can be found at MedlinePlus